The Hindu Business Line : Glenmark introduces cardiac drug in Canada

GLENMARK Pharmaceuticals, an R&D-based pharma company with presence in both the formulations and bulk drugs sector, has commenced supply of Amiodarone, a new general bulk drug in the cardiac segment, to the Canadian market.

The company expects to start supply of the drug in the US market shortly, with the total supplies to the Canadian and US markets likely to touch the $6 million (approximately Rs 27.56 crore) mark in the next 18 months. Glenmark had filed the Drug Master Files (DMF) for this product with the US Federal Drugs Administration (USFDA) about six months ago.

According to a company press release, the company has filed two more DMFs in this month with the USFDA — it plans to file three or four more DMFs in the current fiscal.

For the Canadian market, the company will supply the drug to Apotex, which is considered one of the largest pharmaceutical company in Canada, producing more than 200 generics in dosages and formats.

Apotex has also established a presence through subsidiaries, joint ventures and licensing agreements in Mexico, China, Costa Rica, New Zealand, France, Italy and Russia.

Mr Glenn Saldanha, managing director of the company, said the tie-up with Apotex marks a significant development for the company's API business.

The company had last year acquired the API manufacturing facility of Glaxo SmithKline in Gujarat. The company specialises in segments such as dermatology, internal medicine, pediatrics, gynaecology, ENT and diabetes.

Article E-Mail :: Comment :: Syndication

Stories in this Section
Lombardini plans R&D unit in India

GEAC allegations over Shankinase — Shantha Bio says it followed procedures

Glenmark introduces cardiac drug in Canada

Piaggio to use Baramati plant for exports

Ventura Textiles plans to delist from 3 SEs

Aventis scheme

Zenith informs BSE on delist of shares

Ashika offer for shares in Gandhidham Spinning

Qualified Co. Secys in small towns — DCA urged to review decision

Merven board meet to clear reverse merger

Tata Motors not keen on Ssangyong stake